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Abstract INTRODUCTION: The generation of proper immune response in the tumor environ-
ment seems to be essential in antitumor defense. RCAS1 expression has been shown to 
participate in the regulation of immune cytotoxic activity, metallothionein participates 
in the protection of cells against immune mediated apoptosis. Since MT and RCAS1 
expression is observed within healthy tumor environment we aimed to focus on the 
proteins expression in tumor and its healthy adjacent tissue in invasive ductal breast 
cancer regarding the immune cells presence and activity. 
MATERIAL AND METHODS: RCAS1, metallothionein, CD3, CD56, CD4, CD25, CD69, 
CD68 and CD16 antigens expression was assessed by immunohistochemistry in invasive 
ductal breast cancer. Tissue samples were obtained from 45 patients and were grouped 
according to the presence of lymph nodes metastases. Two groups were obtained: with 
and without lymph nodes metastases. 
RESULTS: Significant differences were observed in RCAS1 and metallothionein expres-
sion in tumor and significant differences in metallothionein expression in healthy stroma 
regarding the presence of lymph nodes metastases. The significantly higher RCAS1 
expression was noticed in tumor in comparison to stroma in patients with the presence 
of lymph nodes metastases. No such difference was observed in patients without the 
metastases. Significantly higher metallothionein expression was identified in tumor than 
in stroma in both groups of patients, with and without lymph nodes metastases. These 
changes in RCAS1 and metallothionein expression were significantly related with the 
changes in the number and activity of immune cells. 
CONCLUSION: RCAS1 and metallothionein expression in breast cancer healthy stroma 
seems to be essential for the coexistence of cytotoxic immune cells and normal epithelial 
cells. The loss of the ability to compensate the growing cytotoxic immune response in 
the environment might participate in the development of tumor spread.
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Introduction
The activity of cytotoxic immune cells is regulated 
by cancer cells and this phenomenon seems to play an 
important role in cancer progression. Lymphocytes ac-
cumulate in cancer vicinity but their cytotoxic activity 
against cancer can be inhibited by cancer itself [1]. The 
cancer and immune cell interaction takes place by many 
factors, the presence of which can be demonstrated in 
cancer cells and in extracellular matrix. The participation 
of RCAS1 (Receptor associated cancer antigen present-
ing on SiSo cells) in the suppression of cytotoxic im-
mune cells in various malignant neoplasms as well as 
the participation of metallothionein in the protection 
against cancer induced apoptosis has been recently pre-
sented [1,2]. RCAS1 expression has been demonstrated 
in various neoplasms cell membranes including breast, 
pancreatic, liver, head and neck, uterine cervix, lungs, 
endometrium cancers [2,4,5]. Recently RCAS1 soluble 
form of protein has been reported to be present in blood 
serum and to preserve the ability to suppress immune 
cytotoxic activity resulting in the tumor escape from 
host immunological surveillance [6]. The lymphocytes 
apoptosis around RCAS1 positive cells has been already 
evaluated. Sonoda has shown that RCAS1 expression 
in uterine cancer cells and in metastatic cells in lymph 
nodes was correlated with growing number of apoptotic 
lymphocytes [7]. Similarly in previous reports RCAS1 
expression has been associated with the number of 
apoptotic lymphocytes adjacent to tumor cells in lung 
cancer and Hodgkin’s disease [4,8]. In vitro studies have 
also demonstrated that the culture of activated lympho-
cytes with RCAS1 peptides led to strong suppression of 
lymphocytes growth and eventually led to apoptotic cell 
death [9]. Reverse correlation between RCAS1 expression 
and cytotoxic mononuclear cells infiltration has been 
found in breast cancer [5]. RCAS1 expression has been 
linked to poor prognostic factors [10]. The participation 
of RCAS1 in the cancerogenesis of early breast cancer has 
been also demonstrated [11].
Metallothionein (MT) is a cystein rich protein and 
its expression is related with the regulation of cell pro-
liferation and death [3,12–14]. MT-1 and MT-2 isoforms 
are ubiquitous in various human cells and cancer cells 
including breast cancer [15-17]. Their expression is 
coregulated by many factors, including: hormones, 
metals, and cytokines [18,19]. A relation between MT 
expression and growing proliferation monitored by im-
munohistochemical detection of Ki-67 in breast cancer 
cells has been shown [14]. MT expression has been also 
connected with reduced apoptosis in nasopharyngeal 
cancer and hepatocellular carcinoma [17,20]. Similarly, 
in breast cancer the down regulation of MT expression 
has been linked to the inhibition of cell growth and the 
development of apoptosis [21]. MT is a potential factor 
playing a role in determining sensitivity of tumor cells to 
apoptosis, and it is an inhibitor of induced apoptosis [3]. 
MT was observed to be a negative regulator of NF-kappa 
B activity [22]. MT may protect cells against p53-medi-
ated apoptosis [23]. High MT expression in breast cancer 
is a negative prognostic factor [12,24]. MT expression 
is also linked to cytotoxic T lymphocytes suppression. 
Metallothionein protecting cancer cells against immune 
mediated apoptosis and inhibiting immune cytotoxic 
activity participate in tumor escape from host immuno-
logical surveillance [25].
A proper level of tumor infiltrating lymphocytes (TIL) 
cytotoxic activity at the tumor site is maintained by pre-
ceding TIL infiltration and accumulation and reaching 
the activity level. Stromal cells seem to participate in the 
interaction between tumor cells and immunological cells. 
MT and RCAS1 expression has been demonstrated not 
only in the tumor tissue, but also in the normal epithe-
lium of the upper respiratory tract mucosa, bone marrow, 
endometrium and placenta [26–32]. The accumulation 
of activated immune cells within normal endometrium is 
a part of reproductive processes, and the MT and RCAS1 
expression has been shown to participate in the regula-
tion of immune cytotoxic activity and in the protection 
of endometrial cells against immune mediated apoptosis 
[27,32]. Since MT and RCAS1 expression is found within 
healthy epithelium of tumor vicinity we aimed to focus 
on the proteins expression in tumor and its healthy adja-
cent tissue in ductal breast cancer regarding the immune 
cells presence and activity. 
Material and methods
Group of patients
In all cases patient’s informed consent was received. 
The approval for the research program from the Ethical 
Committee of the Jagiellonian University in Krakow: 
KBET/379/13/2003 was also obtained. The patients in 
this study were randomly selected. Surgically removed 
material was evaluated to determine histological type 
and metastases of the lymph nodes using histological 
methods in the Department of Patomorphology of the 
Jagiellonian University. The clear surgical margin was 
defined as 1 cm2 area of tumor adjacent tissue macro-
scopically and histological free of neoplasmatic texture. 
The surgical resection line was macroscopically and 
histological free from cancer texture. 
Tissue samples
The study group consisted of 45 patients with breast 
cancer. All women underwent mastectomy with axillary 
lymphadenectomy in 1st General Surgery Department of 
Jagiellonian University. The women age ranged between 
33–78 years (mean age 59 years). In each case invasive 
carcinoma was a dominant component. In all cases 
surgical material was obtained after modified radical am-
putation of the breast according to Patey’s method with 
simultaneous removal of axillary lymph nodes. Surgical 
material was fixed in 10% buffered formalin. Then tissue 
was embedded in paraffin and stained with hematoxylin 
and eosin. Each specimen was inspected to specify tumor 
size and a number of lymph nodes obtained for study. 
Microscopic examination was performed to identify 
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histological type and grade of invasive carcinoma, the 
presence of vessel invasion and tumor metastases to the 
lymph nodes. Histological grades of invasive carcinoma 
were diagnosed according to Bloom and Richardson clas-
sification modified by Elston and Ellis, recommended by 
the National Coordinating Group for Breast Pathology 
[34]. 
Immunohistochemistry 
Immunohistochemical analysis was performed in 
the Patomorphology Department of the Jagiellonian 
University. Five-micrometer slides from each case were 
stained to visualize expression of RCAS1, MT and 
CD16-, CD25-, CD69-, CD4-, CD3-, CD56-positive 
cells (mainly lymphocytes) as well as CD68+ cells, it 
means macrophages. In all cases immunohistochemistry 
was performed applying Envision method using Dako 
Autostainer. The following antibodies were applied: 
mouse monoclonal antibody Anti- RCAS1 (Medical and 
Biological Laboratories, Nakaku Nagoya, Japan in DAKO 
Antibody Diluent with Background Reducing Compo-
nents-DAKO, Denmark, dilution 1:1 000), monoclonal 
mouse antibody ImmunOTM (MP Biomedicals, Inc., 
clone 1A12 in dilution 1:1 000), CD56 (NCAM; NCL-
CD56-504, Novocastra) in dilution 1:100, CD69 (NCL-
CD69, Novocastra) in dilution 1:25, CD25 (Interleukin-2 
Receptor, NCL-CD25-305, Novocastra) in dilution 1:25, 
CD16 (NCL-CD16, Novocastra) in dilution 1:40, CD68 
(Klone PG-M, Dako) in dilution 1:50, according the 
manufacturer’s instructions, CD3 (NCL-CD3p, Novo-
castra) in dilution 1:100 and CD4 (Klone 1F6)in dilution 
1:150. Visualization of reaction products was performed 
using AEC (3-amino-9-ethyl-carbazole) as a chromogen 
(AEC Substrate Chromogen ready-to-use, DAKO, 
Denmark) for 10 minutes at room temperature. Sections 
were counterstained with hematoxylin and mounted in 
glycergel. As a positive control a tonsil specimen was 
taken for RCAS1 and for metallothionein it was a breast 
cancer specimen. All stainings were performed with the 
same procedure but with the omission of the primary 
antibody as a negative control. 
RCAS1 expression was evaluated in entire slides in 
cancer cells and in glandular epithelium lining the ducts 
and acini of healthy stroma, considering the intensity of 
the colour reaction and percentage of cells. MT expres-
sion was evaluated in cancer cells, glandular epithelium 
lining the ducts and acini of healthy stroma and in 
stromal myoepihelial cells. The percentage of cells and 
degree of color reaction in MT-positive cells was ana-
lyzed. The scales used for estimation of the above both 
markers staining is shown in Table 1. 
The immune cells were calculated in an entire speci-
men, in the tumor and in region around tumor and an 
average cell number per 2 hpf (high power field, objec-
tive magnification × 40) was calculated. Variable scales 
were used to evaluate semiquantitatively an amount of 
Table 1. The scale used for evaluation of metallothionein and RCAS1 expression.
Antigen
Immunoreactivity
0 +1 +2 +3
RCAS1 No 
reactivity
Weak (when observed any, also 
granular in paranuclear region) 
cytoplasmic staining pattern in up 
to 10% of positive cells
Marked cytoplasmic (sometimes 
together with membranous) 
staining in 11–30% of the cells
High expression – more than 30% 
of positive cells
Metallothionein Lack of any 
positivity
Weak staining in less than 5% of 
the cells
Moderate – various staining 
intensity but in <50% of the cells,
Strong – staining of more than 
50% of the cells.
Table 2. The scale used for evaluation of CD25, CD56,CD3, CD4, CD68, CD69, and CD16 antigens expression.
Antigen
Immunoreactivity
0 1+ 2+ 3+ 4+
CD 25 Lack of positive cells Single positive cells 1–5 positive cells/1hpf More than 5 positive 
cells/1hpf -
CD 56 Lack of positive cells - - - -
CD 4 Lack of positive cells - - - -
CD 69 Lack of positive cells Single positive cells 1–5 positive cells/1hpf More than 5 positive 
cells/1hpf -
CD 3 Lack of positive cells 1–5 positive cells/1hpf 6–10 cells/1hpf 11–20 positive cells/1hpf More than 20 positive 
cells/1hpf
CD68 Lack of positive cells 1–5 positive cells/1hpf 6–10 cells/1hpf 11–20 positive cells/1hpf More than 20 positive 
cells/1hpf
CD16 Lack of positive cells 1–5 positive cells/1hpf 6–10 cells/1hpf 11–20 positive cells/1hpf More than 20 positive 
cells/1hpf
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the cells, depending of their general number in the speci-
men, what is summarized in the Table 2.
The evaluation of immunohistochemical reactions 
was performed independently by two histopathologists 
(L. R-S. and K. G.).
Statistical analysis
The distribution of variables in the study groups of 
women checked with the use of the Shapiro-Wilk test 
showed that all of them were different from normal. 
Therefore, nonparametric testing was employed. Statisti-
cal significance between the groups was determined by the 
Kruskal-Wallis analysis of variance (ANOVA) test. The 
Mann-Whitney U test was then used as applicable. The 
Spearman rank test was used to evaluate interclass correla-
tion coefficients. All calculations were carried out with the 
use of STATISTICA software v. 6 (StatSoft, USA, 2001).
Results
RCAS1 and MT immunoreactivity was analyzed in 
invasive ductal breast cancer and its healthy stroma. 
RCAS1 expression was identified in cancer nests and in 
glands of healthy stroma. 
MT expression was identified in cancer, glands of 
healthy stroma and in stromal myoepithelial cells. 
The patients were divided into two main groups ac-
cording to the presence of lymph nodes metastases. The 
patients with the presence of lymph nodes metastases 
had statistically significantly lower breast cancer cells’ 
differentiation according to Bloom scale than the patients 
without metastases (p=0.04)
Figure 1. Strong RCAS1 expression (3+) in cancer cells in patient 
with the presence of lymph nodes metastases.
Figure 2. Weak RCAS1 expression (1+) in cancer cells in patient 
without the presence of lymph nodes metastases.
Figure 3. Strong MT immunoreactivity (3+) in cancer cells in patient 
with the presence of lymph nodes metastases..
Figure 4. The lack of MT immunoreactivity in cancer cells, stroma 
and normal glandular cells in patient without the presence of 
lymph nodes metastases..
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Analysis of RCAS1 immunoreactivity
Statistically significantly higher RCAS1 expression 
was observed in the group of tumors with the presence 
of lymph nodes metastases than in the group without 
metastases (p<0.001). No differences in RCAS1 expres-
sion were observed in cancer healthy stroma regarding 
the presence of lymph nodes metastases. RCAS1 expres-
sion in tumor was statistically significantly higher than 
in stroma in patients with the presence of lymph nodes 
metastases (p=0.0002), no such difference was observed 
in patients without the presence of lymph nodes metas-
tases.
The presence of lymph nodes metastases correlated 
with RCAS1 expression (r=0.57, p<0.001). A correlation 
was also observed between RCAS1 expression in tumor 
and the tumor grade/cells differentiation according to 
Bloom scale (r=0.48, p<0.001). We compared RCAS1 
expression and the tumor differentiation using Kruskal-
Wallis analysis of variance (ANOVA) test (p=0.0045). 
RCAS1 expression in Bloom 2 and 3 grades were on 
comparable levels and were statistically significantly 
higher than in Bloom 1 (p<0.01 in both cases). 
Analysis of MT immunoreactivity
MT expression was statistically significantly higher 
in tumors with the presence of lymph nodes metastases 
than in tumors without the presence of lymph nodes 
metastases (p<0.01). Similarly healthy glands adjacent to 
cancer represented statistically significantly higher MT 
expression in cases with the presence of lymph nodes 
metastases in comparison to cases without metastases 
(p=0.01). Tumor stroma represented statistically signifi-
cantly higher MT immunoreactivity in tumors with the 
presence of lymph nodes metastases when compared to 
tumors without metastases (p<0.01). MT expression was 
statistically significantly higher in tumor than in stroma 
in both groups of patients, with and without the presence 
of lymph nodes metastases (respectively in both cases 
p<0.001).
MT expression correlated with the presence of lymph 
nodes metastases in tumor tissue (r=0.46, p<0.01), 
healthy stromal glands (r=0.36, p=0.01) and in myoepi-
thelial cells of healthy stroma (r=0.41, p<0.01). 
The highest level of MT expression was identified 
within tumor tissue, stromal glands and myoepithelial 
cells of healthy stroma in Bloom 2 tumors, while the low-
est level of MT was found in Bloom 1 tumors, however 
the differences were not statistically significant. 
Immune cells
The presence of CD3 positive cells was observed in 
both, tumor and its adjacent healthy tissue. No CD56 
positive cells and no CD4 positive cells were observed 
neither in tumor nor in healthy stroma. The activity of 
immune cells was evaluated by identification of CD25 
and CD69 antigens expression in both, tumor and its 
adjacent healthy stroma. Additionally CD16 and CD68 
antigens expression were evaluated. 
Table 3. The evaluation of RCAS1 immunoreactivity with respect to 
the presence of lymph nodes metastases.
Variables N status
RCAS1 - Immunoreactivity
0 +1 +2 +3
RCAS1 tumor 
expression
N0 (n=22) 40 (9) 45 (10) 5 (1) 10 (2)
N1 (n=23) 21 (5) 34 (8) 34 (8) 11 (2)
RCAS1 
stromal 
expression
N0 (n=22) 63 (14) 27 (6) 5 (1) 5 (1)
N1 (n=23) 60 (14) 30 (7) 5 (1) 5 (1)
Table 4. The analysis of metallothionein expression with respect to 
the presence of lymph nodes metastases.
Variables N status
MT - Immunoreactivity
0 +1 +2 +3
MT cancer 
expression
N0 (n=22) 31 (7) 22 (5) 36 (8) 11 (2)
N1 (n=22) 22 (5) 27 (6) 36 (8) 15 (3)
MT expression in 
the healthy glands 
adjacent to cancer
N0 (n=22) 11 (2) 17 (4) 36 (8) 36 (8)
N1 (n=22) - 5 (1) 27 (6) 68 (15)
MT myoepithelial 
expression
N0 (n=22) 73 (16) 22 (5) 5 (1) -
N1 (n=22) 41 (9) 44 (10) 15 (3) -
Table 5. The comparison of CD3, CD25, CD69, CD16, CD68 antigens 
expression in tumor and its adjacent healthy stroma.
Tumor antigen 
expression
Stromal antigen 
expression p-value
CD3 CD3 0.02
CD25 CD25 0.3
CD69 CD69 0.9
CD16 CD16 0.02
CD68 CD68 0.7
Table 6. The evaluation of RCAS1 and MT immunoreactivity and the 
presence and activity of immune cells.
Proteins Lymphocyte antigen p-value
RCAS1 stroma CD3 stroma 0.07
RCAS1 stroma CD25 stroma 0.02
RCAS1 tumor CD16 tumor 0.02
MT tumor CD3 tumor 0.047
MT stroma CD25 stroma 0.034
The analysis was performed by Kruskal-Wallis analysis of variance 
(ANOVA) test.
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The number of CD3 positive lymphocytes was sta-
tistically significantly higher in tumor adjacent healthy 
stroma in the group of patients without the presence 
of lymph nodes metastases in comparison to the group 
with metastases (p=0.01). The number of CD3 positive 
TIL was higher in the group without the presence of 
metastases in comparison to the group without metas-
tases, but the difference was not statistically significant. 
Similarly, the number of CD25 positive cells was higher 
in the group without metastases in both tumor tissue 
and tumor adjacent healthy stroma in patients without 
the presence of metastases when compared to the group 
with metastases. The expression of CD69 antigen was 
on comparable level in both groups, with and without 
the presence of metastases. CD3 expression correlated 
statistically significantly with CD25 expression (r=0.45, 
p<0.01), and with CD69 (r=0.52, p<0.001) in tumor. 
The presence of immune cells and their activity was 
analyzed in our study regarding the MT immunoreactiv-
ity and RCAS1 immunoreactivity changes within tumor 
and tumor adjacent healthy tissue. The obtained results 
are presented below in Table 6.
Statistically significant correlation was observed 
between RCAS1 tumor expression and CD68 antigen 
expression (0.29, p=0.046) and CD16 antigen expression 
(0.36, p=0.02). Statistically significant correlation was 
also observed between MT stromal glands expression 
and CD25 antigen expression (r=0.27, p=0.06) and 
between MT stromal myoepithelial cells expression and 
CD25 antigen expression (r=0.04, p<0.01). 
Discussion
Statistically significant differences were observed in 
RCAS1 and metallothionein expression in tumor and 
statistically significant differences in metallothionein 
expression in healthy stroma with respect to the presence 
of lymph nodes metastases. These changes in RCAS1 and 
metallothionein expression were significantly related with 
the changes in the number and activity of immune cells. 
RCAS1 expression in breast cancer has already been 
considered however its expression in tumor adjacent 
healthy stroma has not been analyzed yet. RCAS1 is a 
protein responsible for the tumor escape from host im-
munological surveillance. A relation between EBAG9 
(oestrogen receptor-binding fragment associated gene 9) 
gene overexpression the product of which has later been 
identified to be identical with RCAS1 plays an important 
role in the development and progression of breast cancer 
in the early stage of its growth [11]. In 2001 Suzuki 
reported a significant association between ER-alpha (es-
trogen receptor alpha) status and RCAS1 expression [5] 
and confirmed this finding in his further study in 2004 
[35]. The relation between ER-alpha and RCAS1 has been 
statistically significant in ERR-alpha (estrogen related re-
ceptor alfa) positive tumors. ERR possibly modulates the 
expression of ERE containing estrogen responsive genes. 
ERR expression is an independent negative prognostic 
factor, correlates with the recurrence of the disease and 
adverse clinical outcome of the ductal breast carcinoma, 
has been found to be significantly associated with the 
presence of lymph nodes metastases [35]. In our study 
RCAS1 correlated statistically significantly with the 
presence of lymph nodes metastases. Although such a 
correlation has not been identified in the study of Su-
zuki [5]. Additionally, on the contrary to Suzuki report, 
RCAS1 expression in tumor in our study was statistically 
significantly correlated with tumor grade (0.48, p<0.01). 
The patients with the presence of lymph nodes metastases 
had statistically significantly more frequently poorly dif-
ferentiated tumors than the patients without the presence 
of lymph nodes metastases. The statistically significantly 
higher RCAS1 expression was noticed in tumor in com-
parison to stroma in patients with the presence of lymph 
nodes metastases. No such difference was observed in 
patients without the metastases. High RCAS1 expression 
in tumor with the presence of metastases was associated 
with the lower number of CD3 positive TIL and lower 
CD25 expression, this finding confirms Suzuki report 
[35], in which RCAS1 expression was inversely correlated 
with the number of CD3 positive cells. The concomitant 
to tumor dissemination RCAS1 growth in tumor with its 
decrease in stroma may result from the disturbance of 
regulatory mechanisms in the tumor environment what 
might condition the further progression. 
The differences between types of immune cells 
and their activity found between breast cancer and its 
healthy stroma are interesting. Statistically significant 
differences were observed in the number of CD3 positive 
cells and the CD16 antigen expression between tumor 
and its healthy adjacent tissue. The interaction between 
tumor and immune system is still not well understood. 
The ability of tumor cells to regulate the immune cells 
activity seems to be essential for tumor escape from host 
immunological surveillance. It has been already reported 
that tumor cells polarize an antitumor defense into Th2 
response [1]. This phenomenon leads to the down regu-
lation of perforin expression within TIL or to blockade of 
its cytotoxicity trough stimulation of CD94/NKG2A het-
erodimer expression on NK cells and even on other CTLs 
[1]. Predominant Th2 anticancer response may lead to 
down regulation of the cytotoxic potential of TIL, what 
results in the altered cytokines pattern in tumor milieu 
[36]. Cancer cell may alter the functional composition 
of anti-tumor effect cells through the decrease of CD25 
antigen expression [37]. In our study RCAS1 stromal 
immunoreactivity changes were statistically significantly 
associated with CD3 and CD25 antigen stromal expres-
sion. The alteration of the number of TIL subpopulation 
may be realized by mutual affection of various cytokines 
in tumor milieu. The growth or domination of Th2 
polarity is related with the raise of IL-10 in cancer milieu 
and leads to the modulation of IL-12 action. From one 
side IL-12 is essential for the activation of NK cells, from 
the other side IL-12 in the presence of IL-10 may stimu-
late CD94/NKG2A receptor on NK and CTLs [38,39]. 
This complex regulation of immune response show the 
simultaneous inhibitory and activating mechanisms ap-
792 Neuroendocrinology Letters Vol.27 No.6, 2006 • Copyright © Neuroendocrinology Letters ISSN 0172–780X  www.nel.edu Online: node.nel.edu
T. J. Popiela, L. Rudnicka-Sosin, M. Dutsch-Wicherek, M. Klimek, P. Basta, K. Galazka & L. Wicherek
pearing in tumor environment. The observed decreased 
expression of the IL-2 receptor in TIL in tissue adjacent 
to the tumor in breast and cervical cancers has been 
interpreted by Sheu as a result of existence of TIL selec-
tive suppression phenomenon [37]. This can easily be 
explained by selective suppression phenomenon using 
RCAS1 expression. The biological role of the selective 
suppression phenomenon is not clearly understood and 
seems to result from the physiological necessity of the 
coexistence of activated lymphocytes together with ad-
jacent host cells. Our results and these presented above 
indicate that this coexistence is maintained by RCAS1 
stromal expression. The presence of lymph nodes 
metastases is the evidence of tumor dissemination and 
indicates that the selective suppression phenomenon is 
disrupted in tumor environment. 
Activated lymphocytes accumulate in tumor adjacent 
healthy stromal tissue in breast cancer. From one side 
these cells (cancer cells) posses an ability to regulate the 
immune cells activity and from the other side posses also 
mechanisms protecting them from unwanted apoptosis. 
Metallothionein expression promotes cells proliferation 
and protects cells from apoptosis [3]. Mutual interac-
tion between MT2A gene activity and ECRG2 has been 
reported. The product of ECRG2 gene is responsible for 
the inhibition of proliferation and induction of apoptosis 
in esophageal cancer. On the contrary to ECRG2, MT 
promotes cells proliferation and protects cells from 
apoptosis [13]. The homeostasis of cancer cell seems to 
be maintained through the balance between these two 
genes activity/expression. MT plays an important role in 
determining the sensitivity of tumor cells to apoptosis 
[40]. The reduction of MT expression in MCF-7 human 
breast cancer cell line resulted in inhibition of cell growth 
and in the initiating of spontaneous apoptosis [21]. MT 
seems to regulate the process of apoptosis by the influence 
on the Zn2+ intracellular level which proper concentra-
tion is essential for the caspases: 3, 8 and 9 activity [41]. 
MT immunoreactivity represented both cytoplasmic 
and nuclear pattern of staining in breast cancer cells 
[12,14,42]. Similarly to these findings we observed MT 
immunoreactivity in both cytoplasm and nuclei. MT 
expression in cytoplasm is thought to be related with pro-
tection against cytotoxicity while its nuclear expression is 
related with the protection against genotoxicity [23,43]. 
MT expression in breast cancer is a factor of poor prog-
nosis [24,44]. No relationship has been found between 
MT isoforms expression and the expression of estrogen 
receptor in breast cancer [45]. MT expression seems to 
participate in tumorogenesis of estrogen receptors nega-
tive ductal breast cancers [41]. A relationship between 
MT mRNA and the tumor grade has been observed in 
breast cancer, G3 tumors were typified by MT-2A mRNA 
overexpression [14]. MT immunoreactivity in our study 
was observed to be in both tumor and healthy stroma at 
the highest level in G2 tumors and at the lowest level in 
G1 tumors, however the differences were not statistically 
significant. The differences may result from the altera-
tions in mRNA expression and immunohistochemistry 
analysis of intra-cellular distribution [15]. In our study 
differences in MT1/2 reactivity between the epithelium 
and stromal glands as well as in myoepithelial cells were 
observed. No such differences were observed in MT2A 
gene expression, it has been suggested to result from 
gene post-transcriptional regulation rather than from 
gene expression alterations and this might explain the 
relationship between MT1/2 expression raise and can-
cer disease progress [15]. Metallothionein expression 
in breast epithelial cells typifies the malignant ductal 
epithelium [46], while MT expression in myoepithelial 
cells has also been observed in healthy cells [47]. In our 
previous study MT expression was determined in breast 
cancer stroma and was raising statistically significantly 
in tumors with the presence of lymph nodes metastases, 
therefore we suggested that MT expression might result 
from the interaction between spreading tumor cells and 
the cells from healthy adjacent stroma [48]. Statistically 
significantly higher MT expression has been revealed in 
tumor tissue, healthy stromal glands and in myoepithelial 
stromal cells in cases with the presence of lymph nodes 
metastases in this study in comparison of cases without 
lymph nodes metastases. 
MT expression may raise also in response to various 
acute phase cytokine factors including: interleukins (Il-1, 
Il-6), tumor necrosis factor (TNF-alfa) and INF-gamma 
[18,49–51]. Metallothionein seems to participate in the 
interaction between tumor cells and immune cells and 
enables the tumor cells to evade the host defense immune 
response [25]. Young J revealed that MT expression can 
contribute to dramatic decrease of cytolytic activity of 
immune cells and plays an important role in the suppres-
sion of anti tumor immunity [25]. Statistically significant 
correlation between stromal MT immunoreactivity and 
CD25 expression on immune cells was identified in 
our study. Similar observation reported Youn in an in 
vitro study, demonstrating high MT expression with 
high CD25 expression independently of suppression of 
cytolytic CTLs activity. Therefore Youn suggested that 
the participation of MT in tumor escape from the host 
immunological surveillance may be related with its sup-
pression of immune cell’s response and induction of can-
cer cell’s proliferation. MT expression may be secondary 
to accumulating immune cells and the growing cytotoxic 
activity. In our study a statistically significant association 
was identified between MT immunoreactivity changes 
and the presence of CD3 positive cells in tumor and 
between MT stromal immunoreactivity and CD25 an-
tigen stromal expression. MT expression in tumor and 
its healthy adjacent tissue seems to be secondary to the 
activity of immune cells infiltrating tumor and protects 
MT expressing cells against immune mediated apoptosis. 
This phenomenon is necessary also for the assuring 
of tissue integrity during growing cytotoxic response 
against tumor cells and the loss of this ability may lead 
to tumor spread. The tumor environment is typified by 
the MT overexpression which may be the demonstration 
of physiological local processes regulation destruction in 
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cases of the presence of lymph nodes metastases and the 
tumor dissemination occurs. 
Conclusions
The selective suppression of activated immune cells 
and the ability to acquire resistance to immune mediated 
apoptosis are essential factors enabling the interaction 
between activated immune cells with cells of tumor 
adjacent environment. RCAS1 and metallothionein 
expression in breast cancer and its healthy stroma seem 
to be essential for this coexistence. The loss of the ability 
to compensate the growing cytotoxic immune response 
in the environment might participate in the development 
of tumor spread.
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